Previous 10 | Next 10 |
2023-05-09 08:10:56 ET Agenus press release ( NASDAQ: AGEN ): Q1 GAAP EPS of -$0.22 misses by $0.01 . Revenue of $22.9M (-11.7% Y/Y) misses by $0.63M . At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month ...
At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments B...
2023-05-08 14:30:42 ET Agenus ( NASDAQ: AGEN ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $23.53M (-9.3% Y/Y). Over the last 1 year, AGEN has beaten ...
Agenus (Nasdaq: AGEN), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with non-micros...
Agenus (NASDAQ: AGEN) is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing ...
2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-04-27 06:49:19 ET A panel of the European Medicines Agency (EMA) recommended the approval of GSK's ( NYSE: GSK ) respiratory syncytial virus (RSV) vaccine candidate for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older. ...
Oral presentation on Phase 2 trial evaluating balstilimab/zalifrelimab plus standard of care in advanced sarcoma Poster discussion on Phase 1 trial investigating AGEN2373 monotherapy in advanced solid tumors Agenus (Nasdaq: AGEN), a leading immuno-oncology company speciali...
Conference Call on Tuesday, May 9, 2023 at 8:30 a.m. ET Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced the Company will release its first quarter 2023 financial results before the market o...
Agenus (NASDAQ: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences: HC Wainwright BioConnect Investor Con...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...